Pedrano, Mark Jhaydin .

HRN: 21-32-59  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/12/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
05/12/2022
05/18/2022
IV
65mg
Q12 For 7 Days
Pneumonia
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Pneumonia    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: